RespireRx Pharmaceuticals (OTCQB:RSPI) Inc has noted the publication of a paper detailing the company s newest candidate D5-KRM-II-81, which is a so-called.
Glen Rock, N.J., Dec. 06, 2021 (GLOBE NEWSWIRE) RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company”), a leader in the discovery.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
RespireRx Pharmaceuticals Inc. Provides Update on Its Development Programs
RespireRX Pharmaceuticals Inc.April 22, 2021 GMT
Glen Rock, N.J., April 22, 2021 (GLOBE NEWSWIRE) RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and revolutionary treatments to combat diseases caused by disruption of neuronal signaling, is pleased to provide an update on its therapeutic drug development programs.
EndeavourRx
Scientists associated with the Company have been invited by the prestigious journal,
Pharmacology and Therapeutics, to publish a review article describing the preclinical properties of its lead GABAkine compound, KRM-II-81, and its potential clinical therapeutic applications. The multidisciplinary team of authors have been led by Dr. James M. Cook6,7, Distinguished Professor, University of Wisc